Price$12.15+0.37 (+3.14%)
01:30 PM07:45 PM
News · 26 weeks60+55%
2025-12-282026-06-21
Mix3990d
- SEC Filings17(44%)
- Other11(28%)
- Insider8(21%)
- Analyst3(8%)
Latest news
25 items- SECSEC Form 8-K filed by Climb Bio Inc.8-K - Climb Bio, Inc. (0001768446) (Filer)
- SECSEC Form 424B5 filed by Climb Bio Inc.424B5 - Climb Bio, Inc. (0001768446) (Filer)
- SECSEC Form 8-K filed by Climb Bio Inc.8-K - Climb Bio, Inc. (0001768446) (Filer)
- PRClimb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the high dose cohort, with additional data anticipated by year-end 2026 WELLESLEY HILLS, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (ITP) demonstrating an enc
- SECSEC Form EFFECT filed by Climb Bio Inc.EFFECT - Climb Bio, Inc. (0001768446) (Filer)
- SECSEC Form 424B3 filed by Climb Bio Inc.424B3 - Climb Bio, Inc. (0001768446) (Filer)
- INSIDERSEC Form 4 filed by Director Ra Capital Management, L.P.4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Levin Andrew David4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Drapkin Kimberlee C4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Williams Douglas E4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Cumbo Alexander4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Thomas Stephen Basil4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Dunn Judith4 - Climb Bio, Inc. (0001768446) (Issuer)
- SECSEC Form 8-K filed by Climb Bio Inc.8-K - Climb Bio, Inc. (0001768446) (Filer)
- ANALYSTGuggenheim initiated coverage on Climb Bio with a new price targetGuggenheim initiated coverage of Climb Bio with a rating of Buy and set a new price target of $35.00
- SECSEC Form 8-K filed by Climb Bio Inc.8-K - Climb Bio, Inc. (0001768446) (Filer)
- PRClimb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued DevelopmentCompany to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer Initiation of CLYM116 dosing in IgAN patients in Mabworks Phase 2 study expected in Q3 2026 WELLESLEY HILLS, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, its anti-APRIL monoclonal antibody. Clinical data demonstrated a favorable initial safety profile, supporting continued development of CLYM116 in IgA nephropathy (IgAN). These data will be pres
- SECSEC Form S-3 filed by Climb Bio Inc.S-3 - Climb Bio, Inc. (0001768446) (Filer)
- PRClimb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced upcoming presentations for its CLYM116 and budoprutug programs at the European Renal Association Congress 2026, which will be held in Glasgow, Scotland June 3-6, 2026. Climb Bio will present pharmacokinetic/pharmacodynamic modeling from nonhuman primates to humans for CLYM116, a novel ‘sweeper' anti-APRIL monoclonal antibody, which is being developed to treat IgA nephropathy (IgAN). Initial safety data from the ongoing CLYM116 Phase 1 study in healthy volunteers will also be presen
- PRClimb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 CongressWELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced an upcoming presentation on its budoprutug program at the European Hematology Association (EHA) 2026 Congress, which will be held in Stockholm, Sweden June 11-14, 2026. Climb Bio will present data, including safety, B-cell depletion and initial platelet data from the low dose cohort (250mg at 24 weeks), from the ongoing Phase 1b/2a trial of budoprutug, a novel anti-CD19 monoclonal antibody, in previously treated patients with primary immune thrombocytopenia (ITP). Abstracts are av
- PRClimb Bio to Present at Upcoming Investor ConferencesWELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below. H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQFormat: Fireside ChatDate: Tuesday, May 19 Time: 11:00 – 11:30 a.m. ET Jefferies Global Healthcare Conference Format: Fireside ChatDate: Thursday, June 4 Time: 2:35 – 3:05 p.m. ET The live webcasts will be accessible via the "Investors & Media" section of the Climb Bio website. Webcast replays will be available on
- SECSEC Form 10-Q filed by Climb Bio Inc.10-Q - Climb Bio, Inc. (0001768446) (Filer)
- SECClimb Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Climb Bio, Inc. (0001768446) (Filer)
- PRClimb Bio Reports First Quarter 2026 Financial Results and Provides Business UpdatesRobust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ERA 2026 with initial Phase 1 PK/PD data expected mid-2026 Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; anticipate data from all ongoing trials in 2026 Secured $110 million private placement led by top-tier healthcare investors WELLESLEY HILLS, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the first quarter
- SECClimb Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Climb Bio, Inc. (0001768446) (Filer)
CLYM FAQ
6 questionsWhere does CLYM stock trade?
Climb Bio Inc. (CLYM) is listed on NASDAQ.What sector and industry is CLYM in?
Climb Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Climb Bio Inc. go public?
Climb Bio Inc. (CLYM) completed its IPO in 2021.What are analysts saying about CLYM?
Climb Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $3500.00 price target on 2026-06-08. Recent price targets range from $1200.00 to $3500.00.What companies are similar to CLYM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CLYM side-by-side with any of them on Quantisnow.How can I track CLYM on Quantisnow?
Quantisnow aggregates Climb Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLYM to receive live email and push alerts on every new disclosure.